Physician profile
Stacy Halderman
NPI 1558836510
$3,802.63
in general payments reported to CMS, 2019-2025
36 companies · $729 in 2025
The $729 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $952 · 2022: $667 · 2023: $770 · 2024: $686 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,183.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $384.41 | 2021-2023 | Ajovy |
| Abbott Laboratories | $371.04 | 2021-2025 | Freestyle Libre 3, Mitraclip |
| Astrazeneca Pharmaceuticals LP | $365.09 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $339.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $318.06 | 2021-2025 | |
| Lilly USA, LLC | $206.15 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $201.82 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $186.78 | 2021-2025 | |
| Amgen INC. | $174.10 | 2023-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $158.70 | 2023-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $136.25 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.37 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $115.21 | 2021-2023 | Steglatro, Belsomra |
| Sumitomo Pharma America, INC. | $73.98 | 2025 | Gemtesa |
| Eisai INC. | $62.46 | 2021-2025 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Halderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.